GLP Watchdog

Embody vs Hims

Hims has an open FDA warning letter dated September 9, 2025. Embody has none. No price lines up like for like: Embody and Hims publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Embody / Hims

Featured pick (affiliate partner)

Embody logo

Embody

9.3/10

Hims logo

Hims

6.7/10

FDA warning letters
None on record
Pharmacy
Lowest standing price
$79/moCompounded semaglutide injection
$149/moBrand-name semaglutide pill, medication only, membership extra
States
All 50 states and DC
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Embody
Visit Hims

Embody is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Hims pays us nothing. The scores are computed the same way for both and are shown as computed (Embody 9.3, Hims 6.7). How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. Embody has none.

  2. 02

    Embody names four pharmacies. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like: Embody and Hims publish prices for different products.

  4. 04

    Only Embody lists a price for compounded semaglutide injection, compounded tirzepatide injection and compounded oral tirzepatide. Only Hims lists a price for brand-name semaglutide pen, brand-name tirzepatide pen and brand-name semaglutide pill.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Embody

Hims

Compounded semaglutide injection

$79/mo

$948 a year

Not sold or not priced
Compounded tirzepatide injection

$129/mo

$1,548 a year

Not sold or not priced
Brand-name semaglutide pen
Not sold or not priced

$199/mo

medication only, membership extra; not compared

Brand-name tirzepatide pen
Not sold or not priced

$299/mo

medication only, membership extra; not compared

Compounded oral tirzepatide

$329/mo

$3,948 a year

Not sold or not priced
Brand-name semaglutide pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Foundayo (orforglipron) pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Price includes
Medication, clinician visits, shipping
Medication
Billed separately
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the one-month plan; 3-, 6- and 12-month plans are prepaid
Monthly membership, auto-renews
Refunds
No refunds once paid; a partial refund only after a medical disqualification
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Early-exit fee
None stated
None stated

Read off each seller’s own pages. Embody: October 30, 2026. Hims: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Embody

9.3/10
Featured pick (affiliate partner)
  • No FDA warning letter on record
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Hims does not price
  • Price includes clinician visits
Visit Embody

The case for Hims

6.7/10
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Embody does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

Scores

Embody 9.3 · Hims 6.7 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

9.0A
vs
B
6.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
3.0

The score is the same formula for every seller. Payment does not enter it. Method

Embody vs Hims: questions

Hims has an open FDA warning letter dated September 9, 2025. Embody has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Embody names four pharmacies. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like: Embody and Hims publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Embody states you can cancel at any time; refunds: no refunds once paid; a partial refund only after a medical disqualification. Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed.
Embody is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Hims pays us nothing. The scores are computed the same way for both and are shown as computed (Embody 9.3, Hims 6.7).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks